ProMIS Neurosciences to Present at Key Investor Conferences Amid Critical Alzheimer’s Trial
Event summary
- ProMIS Neurosciences will participate in four investor conferences in September 2026, including fireside chats and presentations.
- CEO Neil Warma and CMO Dr. Larry Altstiel will discuss the EpiSelect™ platform and lead candidate PMN310 in the PRECISE-AD Phase 1b trial.
- 12-month topline data from the PRECISE-AD trial is anticipated in early 2027.
- ProMIS marked World Alzheimer’s Day with Nasdaq on September 21, 2026.
The big picture
ProMIS Neurosciences is leveraging high-profile investor conferences to amplify its clinical narrative as it awaits critical data from its Phase 1b trial in early Alzheimer’s disease. The company’s focus on toxic misfolded proteins positions it within a competitive but high-stakes segment of neurodegenerative disease research, where success in PMN310 could redefine its valuation and strategic partnerships.
What we're watching
- Trial Momentum
- The pace at which ProMIS can translate interim data into broader clinical validation for PMN310.
- Investor Sentiment
- Whether the upcoming conference presentations can sustain or elevate market confidence ahead of 2027 topline data.
- Competitive Positioning
- How ProMIS differentiates its EpiSelect™ platform in the crowded Alzheimer’s therapeutic landscape.
Related topics